ELIOS准分子激光小梁切开术与iStent inject联合超声乳化术的疗效与安全性比较
这项多中心回顾性队列研究比较了超声乳化联合ELIOS与联合iStent植入在轻中度青光眼患者中的1年疗效与安全性。两组眼压降幅相似(21.6% vs 20.7%,p=0.74),但Phaco-ELIOS组获得用药减少的患者比例更高(46.4% vs 31.3%,p=0.02),不良事件和再次青光眼手术率均低且相当。
要点
- Phaco-ELIOS与Phaco-iStent在1年眼压降幅上无显著差异(p=0.74)。
- Phaco-ELIOS组用药减少比例更高(46.4% vs 31.3%,p=0.02)。
- 两组不良事件及再次青光眼手术率均低且相当。
核心结论
- Phaco-ELIOS与Phaco-iStent提供相当的1年眼压降幅和总体安全性。
- Phaco-ELIOS在局部用药减少方面表现出更多患者获益。
研究设计与样本
- 多中心回顾性队列研究,纳入2020至2025年间三家欧洲中心接受联合手术的患者。
- 共343眼(Phaco-ELIOS组164眼,Phaco-iStent组179眼),70%有1年随访数据。
- 主要终点为术后12个月眼压,次要终点包括纵向眼压和用药、手术成功率、不良事件及再次青光眼手术需求。
主要发现
- Phaco-ELIOS组平均眼压下降21.6%,Phaco-iStent组下降20.7%,12个月内保持稳定(p=0.74)。
- 术后局部青光眼用药减少量两组相似(0.56 vs 0.41;p=0.2)。
- Phaco-ELIOS组用药减少患者比例更高(46.4% vs 31.3%;p=0.02)。
- 两组不良事件率和再次青光眼手术率均低且相当。
关键数值与推荐
- 主要终点为术后12个月眼压。
- 用药减少定义为局部青光眼药物数量减少。
- 手术成功、不良事件和再次青光眼手术为次要评价指标。
临床怎么用
- 对于轻中度青光眼合并白内障患者,Phaco-ELIOS可作为有效的联合MIGS选项。
- 若优先考虑减少局部降眼压药物使用,Phaco-ELIOS可能更具优势。
- 两种联合手术安全性均良好,可根据患者具体情况选择。
局限性
- 回顾性研究设计可能存在选择偏倚。
- 仅70%患者有1年随访数据。
- 纵向结果采用多重插补法分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: Minimally invasive glaucoma surgery (MIGS) procedures are commonly combined with phacoemulsification to provide additional intraocular pressure (IOP) and/or topical medication reduction in patients with mild-to-moderate glaucoma. This study compared the 1-year efficacy and safety of excimer laser trabeculostomy (ELIOS) versus trabecular micro-bypass stenting (iStent inject and iStent inject W), both performed in combination with cataract surgery. METHODS: This multicentre retrospective cohort study included patients undergoing combined phacoemulsification with either ELIOS (Phaco-ELIOS) or iStent implantation (Phaco-iStent) at three European centres between 2020 and 2025. The primary endpoint was IOP at 12 months postoperatively. Secondary endpoints included longitudinal IOP and medication use, surgical success, adverse events and the need for secondary glaucoma surgery. Longitudinal outcomes were analysed using multiple imputation. RESULTS: A total of 343 eyes were included (164 Phaco-ELIOS and 179 Phaco-iStent), with 1-year follow-up available in 70%. Mean IOP decreased by 21.6% for Phaco-ELIOS and 20.7% for Phaco-iStent and remained stable through 12 months (p=0.74). Both procedures were associated with a similar reduction in postoperative topical glaucoma medications (0.56 vs 0.41; p=0.2). With Phaco-ELIOS, a higher proportion of eyes achieved medication reduction (46.4% vs 31.3%; p=0.02). Rates of adverse events and secondary glaucoma surgery were low and comparable in both groups. CONCLUSION: Phaco-ELIOS and Phaco-iStent provided comparable 1-year IOP reduction and overall safety. Phaco-ELIOS showed a greater number of patients with topical medication reduction, supporting its role as an effective combined MIGS option in patients undergoing cataract surgery.
引用
- Jacobs T, De Crom RMPC, Van Eijgen J, et al. Efficacy and safety of ELIOS excimer laser trabeculostomy versus iStent inject as an adjunct to phacoemulsification: a retrospective comparative study. Br J Ophthalmol. 2026. PMID: 42660628. doi:10.1136/bjo-2026-329700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。